Betalin Therapeutics seeks to eliminate the need for insulin injections and glucose testing in diabetes patients with its proprietary transplanted Engineered Micro Pancreas (EMP).

The EMPtechnology helps create connective tissue that enables the body's beta cells to function properly and produce adequate and functional insulin.Betalin Therapeutics licensed the novel EMP technology developed at the Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015.

The Hebrew University continues to partner with Betalin Therapeutics to support the research and development.